Of interest, it has been noted previously that Bcl-2-positive non-GCB DLBCL tumors may benefit proportionally more from the addition of rituximab to CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) regimens than Bcl-2-negative non-GCB tumors [9], narrowing differences in survival, which may explain this finding in our study. Here, BCL2 is linked to diffuse large B-cell lymphoma.